Zinc lozenges for children's colds: what the pediatric trials show

The case for zinc lozenges in adult colds is real but specific: zinc acetate or gluconate at doses above 75 mg/day, started within 24 hours of symptom onset, can shorten cold duration by roughly one to two days. Translating that into pediatrics turns out to be harder than it sounds. Children can't reliably suck a lozenge for the required 20-30 minutes, oral zinc syrup absorbs differently, and the safety considerations push the practical age limit higher than parents typically realize.

Why the lozenge form matters mechanistically

Zinc is thought to inhibit rhinovirus replication by interfering with viral capsid assembly. The local concentration of zinc ions in the oropharynx during slow dissolution of a lozenge is much higher than what an oral syrup or capsule can achieve in the same tissue [1]. This is why dissolved lozenges have produced positive trials and equivalent oral doses of zinc syrup or capsules have not. The therapeutic mechanism is local, not systemic, which makes the dosage form load-bearing.

Pediatric efficacy trials

A 2007 Cochrane-style review of pediatric zinc trials in colds identified five trials with mixed results: two reported shorter cold duration with zinc, three reported no effect [2]. A 2011 systematic review including 15 pediatric trials found no significant overall effect of zinc on cold duration or severity in children aged 1-12 years, although adverse effects (bad taste, nausea, oral discomfort) were common [3]. The most recent 2024 update by the same group found that the limited positive signal in pediatrics is restricted to high-dose zinc acetate lozenges in children old enough to use them correctly, generally over age 8 [4].

The aspiration and choking risk

The American Academy of Pediatrics and the U.S. Consumer Product Safety Commission consider hard candy lozenges a choking hazard in children under 5 [5]. Most zinc lozenge manufacturers label products for ages 12 and above for this reason. Some pediatric-marketed zinc products use a softer lozenge or a melt-in-mouth tablet, but these dissolve faster than the 20-30 minute window used in the positive efficacy trials, which likely reduces the local exposure that drives the antiviral effect.

Zinc syrup and the WHO acute diarrhea use case

The strongest pediatric evidence for zinc supplementation is not for colds but for acute infectious diarrhea, where the WHO recommends 10-20 mg/day of elemental zinc for 10-14 days in children over 6 months [6]. This use case is settled science and reduces diarrhea duration by 12-25% in pooled trials. The cold-prevention case is a separate, less consistent literature; daily prophylactic zinc syrup has shown modest reductions in cold incidence in zinc-deficient children, but not in zinc-replete populations.

Safety: hyposmia and zinc-induced copper deficiency

Intranasal zinc gluconate (Zicam and similar products) was withdrawn after FDA reports of permanent loss of smell. Oral zinc lozenges do not carry this risk but can produce GI upset at doses above 50 mg in children. Chronic zinc intake above 25 mg/day can produce copper deficiency over months, manifesting as anemia, neuropathy, and immunosuppression [7]. Short courses of zinc lozenges (5-7 days) at typical pediatric doses do not produce this complication, but cumulative use across multiple cold seasons should be monitored.

Bottom line

Zinc lozenges have a real but small effect on cold duration in adults and older adolescents who can use them correctly. In children under approximately 8 years, the form is impractical and the choking risk is meaningful; in younger children, zinc syrup has not produced consistent cold benefit. The strongest pediatric zinc use case is short-course supplementation for acute diarrhea, not cold prevention or treatment.